Poor drug sales hit Gilead Irish revenues

Lower sales of treatment products for hepatitis C, particularly in the US and Japan, led to a 42% collapse in revenues at the main Irish operations of US pharmaceutical giant Gilead last year.

Gilead makes HIV and hepatitis drugs at its Cork facilities and exports drugs to over 100 countries.